Frédéric Toussaint
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Frédéric Toussaint has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Alvaro Moreira
Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany
1 shared publication - Carola Berking
Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), CCC Erlangen-EMN, Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany
1 shared publication E. Grosch
Department of Dermatology Universitätsklinikum ErlangenFriedrich‐Alexander‐University Erlangen‐Nuremberg (FAU) Erlangen Germany
1 shared publicationG. Schuler
Department of Dermatology Universitätsklinikum ErlangenFriedrich‐Alexander‐University Erlangen‐Nuremberg (FAU) Erlangen Germany
1 shared publication- Gerold Schuler
Department of Dermatology, Universtitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Hartmannstraße 14, 91052 Erlangen, Germany
1 shared publication - Kinan Hayani
Department of Dermatology and Allergy, LMU, University Hospital, Munich, Germany
1 shared publication
Latest Publications
- Open Access
- 7 August 2020
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 184 (2) , 345-347
Transient response to nivolumab and relapse after infliximab in a patient with primary cutaneous CD8‐positive aggressive epidermotropic cytotoxic T‐cell lymphoma
- 7 August 2020
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 184 (2) , 345-347
Open AccessTransient response to nivolumab and relapse after infliximab in a patient with primary cutaneous CD8‐positive aggressive epidermotropic cytotoxic T‐cell lymphoma
- Open Access
- 8 February 2020
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 146 (4) , 1079-1088
Guidelines for uveal melanoma: a critical appraisal of systematically identified guidelines using the AGREE II and AGREE-REX instrument
Purpose: Clinical practice guidelines provide recommendations for the management of diseases. In orphan conditions such as uveal melanoma (UM), guideline developers are challenged to provide practical and useful guidance even in the absence of high-quality evidence. Here, we assessed the methodological quality and identified deficiencies of international guidelines on UM as a base for future guideline development. Methods: A systematic search was carried out in guideline databases, Medline and Embase until 27th May 2019 for guidelines on UM published between 2004 and 2019. Five independent reviewers assessed the methodological quality of the identified guidelines using the instruments “Appraisal of Guidelines for Research and Evaluation II” (AGREE II) and AGREE-REX (Recommendation EXcellence). Descriptive analysis was performed and subgroup differences were explored with the Kruskal–Wallis (H) test. The relationship between the individual domains and items of the instruments were examined using Spearman’s correlation. Results: Five guidelines published from 2014 to 2018 by consortia of the United States of America, Canada and the United Kingdom (UK) were included. The highest scores were obtained by the UK guideline fulfilling 48–86% of criteria in AGREE II and 30–60% for AGREE-REX. All guidelines showed deficiencies in the domains “editorial independence”, “applicability”, and “recommendation”. Subgroup differences were identified only for the domain “editorial independence”. Conclusion: The UK guideline achieved the highest scores with both instruments and may serve as a basis for future guideline development in UM. The domains “editorial independence”, “recommendation”, and “applicability” were identified as methodological weaknesses and require particular attention and improvement in future guidelines.
- 8 February 2020
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 146 (4) , 1079-1088
Open AccessGuidelines for uveal melanoma: a critical appraisal of systematically identified guidelines using the AGREE II and AGREE-REX instrument
Purpose: Clinical practice guidelines provide recommendations for the management of diseases. In orphan conditions such as uveal melanoma (UM), guideline developers are challenged to provide practical and useful guidance even in the absence of high-quality evidence. Here, we assessed the methodological quality and identified deficiencies of international guidelines on UM as a base for future guideline development. Methods: A systematic search was carried out in guideline databases, Medline and Embase until 27th May 2019 for guidelines on UM published between 2004 and 2019. Five independent reviewers assessed the methodological quality of the identified guidelines using the instruments “Appraisal of Guidelines for Research and Evaluation II” (AGREE II) and AGREE-REX (Recommendation EXcellence). Descriptive analysis was performed and subgroup differences were explored with the Kruskal–Wallis (H) test. The relationship between the individual domains and items of the instruments were examined using Spearman’s correlation. Results: Five guidelines published from 2014 to 2018 by consortia of the United States of America, Canada and the United Kingdom (UK) were included. The highest scores were obtained by the UK guideline fulfilling 48–86% of criteria in AGREE II and 30–60% for AGREE-REX. All guidelines showed deficiencies in the domains “editorial independence”, “applicability”, and “recommendation”. Subgroup differences were identified only for the domain “editorial independence”. Conclusion: The UK guideline achieved the highest scores with both instruments and may serve as a basis for future guideline development in UM. The domains “editorial independence”, “recommendation”, and “applicability” were identified as methodological weaknesses and require particular attention and improvement in future guidelines.
- 26 June 2018
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 179 (3) , 747-749
Effective anti-programmed death-1 therapy in aSUFU-mutated patient with Gorlin-Goltz syndrome
We present the case of a 77-year-old male patient with more than 50 basal cell carcinomas on the head and upper trunk. The patient did not respond to several lines of treatment, including surgery, imiquimod, retinoids, itraconazole and therapy with the hedgehog inhibitor vismodegib. The patient responded well to off-label therapy with the anti-programmed death-1 antibody pembrolizumab after four infusions.
- 26 June 2018
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 179 (3) , 747-749
Effective anti-programmed death-1 therapy in aSUFU-mutated patient with Gorlin-Goltz syndrome
We present the case of a 77-year-old male patient with more than 50 basal cell carcinomas on the head and upper trunk. The patient did not respond to several lines of treatment, including surgery, imiquimod, retinoids, itraconazole and therapy with the hedgehog inhibitor vismodegib. The patient responded well to off-label therapy with the anti-programmed death-1 antibody pembrolizumab after four infusions.